Navigation Links
Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
Date:2/13/2008

Ventas's 2007 Investments Totaled Approximately $2.2 Billion Ventas Expects 2008 Normalized FFO Per Common Share to Range between $2.75

and $2.82 2008 FIRST QUARTER DIVIDEND INCREASES EIGHT PERCENT TO $0.5125 PER SHARE

LOUISVILLE, Ky., Feb. 13 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") said today that full year 2007 normalized Funds from Operations ("FFO") per diluted common share rose ten percent to $2.69, compared to $2.44 last year. Normalized FFO increased 30 percent in 2007 to $330.6 million, compared to $255.2 million in 2006.

Normalized FFO for the fourth quarter of 2007 rose 23 percent to $87.7 million, versus $71.2 million for the fourth quarter of 2006. Normalized FFO per diluted common share in the fourth quarter of 2007 decreased one percent to $0.66, from $0.67 per diluted common share for the comparable 2006 period. FFO per diluted common share, as defined by the National Association of Real Estate Investment Trusts ("NAREIT"), in the fourth quarter of 2007 increased nine percent to $0.75, from $0.69 per diluted common share for the comparable 2006 period. Both periods reflect the increase in annual rent from the Company's tenant Kindred Healthcare, Inc. (NYSE: KND) ("Kindred") that became effective in the third quarter of 2006.

During the fourth quarter and year, the Company benefited from both internal growth and accretive acquisitions, offset by the Company's increase in outstanding shares and general and administrative costs, which are principally related to Ventas's acquisition of Sunrise Senior Living Real Estate Investment Trust ("Sunrise REIT") in 2007.

Weighted average diluted common shares outstanding in the fou
'/>"/>

SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related medicine news :

1. Ventas Completes Previously Announced Sale of Common Stock
2. Ventas Enters Agreement to Sell Common Stock
3. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
4. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
5. Ventas Appoints Brush SVP - Senior Housing Development and Operations
6. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
7. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
8. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
9. AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share
10. Allscripts Reports Fourth Quarter 2007 Results
11. IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008).../ -- The Providence Service,Corporation (Nasdaq: ... Company,s,Chief Operating Officer, has been appo...orris, appointment fills the vacancy left by the A...eturns the board to six members. Mr.,Norris will... Mr. Norris, age 41, has been with Providence sinc...
(Date:11/21/2008)...que to combat cancer, study says, , ,...rchers have discovered that some cancer cells use ...ght lead to new treatments that starve and kill th...lls in the body need to produce energy. They do th...ires oxygen. Compared with normal cells, tumor cel...
(Date:11/21/2008)...ect Investment And Restore Shareholder Value , ...-- Dr. Stephen Joffe, Craig Joffe, and Alan Buckey...th the U.S. Securities and Exchange Commission. T...ip of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV ),...on correction centers in 33 states in the United S...
(Date:11/21/2008)...l/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL ) to... approved the proposals submitted to them relating...s Industries Ltd. (Nasdaq: TEVA ). , , "... of the transaction by the Barr shareholders," sai...e pleased with the progress that we continue to ma...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
... year received gifts for Christmas that may result...ly confine children to their houses and thereby ma...t Wales Institute of Higher Education (NEWI) revea...kids. X-mas gifts fail to encourage children to go...
...nne Murabito and team have reported that the risk ...ho have their siblings with heart disease.// Thoug...t disease is genetically susceptible and risk incr...dy has shown a 45% increased risk of heart disease...
...ng comes a study that states that about one-third ...o 49 years) in the U.S. have poor cardio respirato...holesterol and blood pressure levels. The study is...JAMA. There has been a strong correlation betwee...
...on children’s will be hi-tech whiz kids but would ...o indoor games with no physical activity.// A surv...er Education found that there is an increase in ob...nd poor diet rich in fatty foods due to fast food....
Other Medicine News:
(Date:11/20/2008)...swire-FirstCall/ -- Duska Therapeutics,Inc., (OT...as submitted its,pivotal Phase 3 ATPace clinical ...l Assessment (SPA) procedure with the U.S. Food an...securing an agreement with the FDA, Duska intends ...placebo-controlled and randomized Phase 3,clinica...
(Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
(Date:11/19/2008)...PRNewswire-FirstCall/ -- Amgen,(Nasdaq: AMGN ) ...sidiary of,Takeda Pharmaceutical Company Limited ...he Phase 3 MONET1 trial evaluating motesanib (AMG ...in for the first-line treatment of,advanced non-s... suspended,following a planned safety data review...
(Date:11/19/2008)...ewswire/ -- Biotech scientists increasingly are ap...h to better understand the effects of novel drug c...Genetic Engineering & Biotechnology News ( GE...t a new compound,s mechanism of action and eventua...according to the November 15 issue of GEN . ( htt...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2World Famous DavidBartonGym Buffs up the Bravern 12788 1World Famous DavidBartonGym Buffs up the Bravern 12788 2World Famous DavidBartonGym Buffs up the Bravern 12788 3Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 1Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 2Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 3Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 4Plexus Systems Inc Names Stosz to Solutions Engineer 12783 1Plexus Systems Inc Names Stosz to Solutions Engineer 12783 2Plexus Systems Inc Names Khanna to Senior Account Manager Western Region 12779 1Plexus Systems Inc Names Khanna to Senior Account Manager Western Region 12779 2
...INESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals...essor of,Pharmacology and Executive Vice President...tute at Albany College of Pharmacy,will present n...ombotic effect of Othera,s lead compound, OT-551, ... previous ocular,studies on OT-551 eye drops, as w...
..., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen...at,preliminary interim clinical data on intravenou...) inhibitor being investigated,for the treatment o...ming major medical meetings. , One oral and one po...lts with belinostat will be made at the 2007 Ameri...
Other Medicine Technology:Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 2Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 3Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5
Wet-Field Hemostatic Eraser bipolar tip, packsize is 5/box.
Sterile cordless eraser tips, packsize is 10/box.
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium.
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium.
Medicine Products: